Case 1:22-cv-00252-MSG Document 361-3 Filed 06/21/24 Page 1 of 6 PageID #: 21785
`Case 1:22-cv-00252-MSG Document 361-3 Filed 06/21/24 Page 1 of 6 PagelD #: 21785
`
`
`
`
`
`
`
`
`
`EXHIBIT 1
`EXHIBIT 1
`
`

`

`Case 1:22-cv-00252-MSG Document 361-3 Filed 06/21/24 Page 2 of 6 PageID #: 21786
`
`IN THE UNITED STATES DISTRICT COURT
`
`FOR THE DISTRICT OF DELAWARE
`
`ARBUTUS BIOPHARMA CORPORATION
`and GENEVANT SCIENCES GmbH,
`
`
`
`)
`)
`)
`
`))
`
`
`
`) C.A. No. 22-252-MSG
`)
`
`
`))
`
`Plaintiffs,
`
`v.
`
`MODERNA, INC. and MODERNATX, INC.,
`
`Defendants.
`
`)
`
`
`PLAINTIFFS’ FOURTH SET OF INTERROGATORIES (NO. 18)
`
`
`
`
`Pursuant to Federal Rules of Civil Procedure 26 and 33, Plaintiffs Arbutus Biopharma
`
`Corporation (“Arbutus”) and Genevant Sciences GmbH (“Genevant”) request that Defendants
`
`Moderna, Inc. and ModernaTX Inc. (collectively, “Moderna” or “Defendants”) respond fully, in
`
`writing, under oath, separately to each interrogatory below. Plaintiffs request that Defendants
`
`serve their written responses to these interrogatories upon Williams & Connolly LLP, 680 Maine
`
`Avenue SW, Washington, DC, 20024, within 30 days after service hereof.
`
`DEFINITIONS & INSTRUCTIONS
`
`Plaintiffs incorporate herein by reference as though fully set forth herein the definitions
`
`and instructions of Plaintiffs’ First Set of Interrogatories to Defendants served February 16, 2023.
`
`INTERROGATORY NO. 18
`
`INTERROGATORY
`
`For each contract for sale of the Accused Product that Moderna contends is not an
`
`infringing sale because the product was not imported into or manufactured in the United States
`
`(whether or not Moderna also has other bases for contending such sale was not an infringing sale),
`
`identify:
`
`1
`
`

`

`Case 1:22-cv-00252-MSG Document 361-3 Filed 06/21/24 Page 3 of 6 PageID #: 21787
`
`(1) the parties to the contract, the date of the contract, the number of doses sold under the
`contact, and the price per dose;
`(2) each location at which the Accused Product sold pursuant to the contract was
`manufactured, warehoused, or delivered, and the quantity of doses manufactured,
`warehoused, or delivered at each such location;
`(3) the name of each Moderna employee, officer, or director who participated in pricing or
`contract negotiations (including any post-sale negotiations) or who signed the contract; for
`each such Moderna employee, officer, or director, also identify his or her office location,
`role in the negotiations and, if he or she signed the contract, the location from which he or
`she signed (see Halo Elecs., Inc. v. Pulse Elecs., Inc., 831 F.3d 1369, 1378 (Fed. Cir. 2016)
`(identifying the location of “pricing and contracting negotiations” and “the final formation
`of a contract for sale” as relevant factors));
`(4) 4.The date(s), location(s), and all attendees with their office locations of all in-person
`meetings during which negotiations of the contract occurred (see Halo Elecs., 831 F.3d at
`1378 (identifying the location of “pricing and contracting negotiations” as a relevant
`factor));
`(5) any and all locations from which purchase orders pursuant to the contract were issued or
`received and the location of the Moderna person(s) responsible for reviewing and
`confirming such purchase orders (see Halo Elecs., 831 F.3d at 1378 (identifying the
`location where the defendant received “the actual purchase orders for those products” as a
`relevant factor);
`(6) any and all locations of Moderna personnel responsible for manufacturing planning and
`order fulfilment for the Accused Products sold pursuant to the contract (see Carnegie
`Mellon Univ. v. Marvell Tech. Grp., Ltd., 807 F.3d 1283, 1309 (Fed. Cir. 2015) (identifying
`the location of “specific contractual commitments for specific volumes” as a relevant
`factor));
`(7) any and all entities that received payments pursuant to the contract and the location of each
`such entity, including the identity of each bank that received payments and the location of
`such bank (see Halo Elecs., 831 F.3d at 1378 (identifying the location where the defendant
`“was paid” as a relevant factor));
`(8) the name of each Moderna employee, officer, or director who participated in marketing
`campaigns related to the contract, the role such person played in the marketing campaign,
`and their respective office locations (see Halo Elecs., 831 F.3d at 1378 (identifying the
`location where “marketing activities took place” as a relevant factor)); and
`(9) each location of product research and development activities, or clinical testing (including
`decisions on the design of clinical tests) regarding the Accused Product that was cited or
`relied upon as part of obtaining or maintaining regulatory approval for the Accused Product
`sold pursuant to the contract, and a description of the work done at each location; (see
`Marvell Tech., 807 F.3d at 1309 (identifying the location where “activities related to
`designing, simulating, testing, evaluating, [and] qualifying” the accused product occurred
`as relevant factors)).
`
`
`
`
`
`
`
`2
`
`

`

`Case 1:22-cv-00252-MSG Document 361-3 Filed 06/21/24 Page 4 of 6 PageID #: 21788
`
`/s/ Nathan R. Hoeschen
`John W. Shaw (No. 3362)
`Karen E. Keller (No. 4489)
`Nathan R. Hoeschen (No. 6232)
`Emily S. DiBenedetto (No. 6779)
`SHAW KELLER LLP
`I.M. Pei Building
`1105 North Market Street, 12th Floor
`Wilmington, DE 19801
`(302) 298-0700
`jshaw@shawkeller.com
`kkeller@shawkeller.com
`nhoeschen@shawkeller.com
`edibenedetto@shawkeller.com
`Attorneys for Plaintiffs
`
`OF COUNSEL:
`David I. Berl
`Adam D. Harber
`Thomas S. Fletcher
`Jessica Palmer Ryen
`Shaun P. Mahaffy
`Jihad J. Komis
`Anthony H. Sheh
`Matthew W. Lachman
`Philip N. Haunschild
`Falicia Elenberg
`WILLIAMS & CONNOLLY LLP
`680 Maine Avenue S.W.
`Washington, DC 20024
`(202) 434-5000
`Attorneys for Plaintiff Genevant
`Sciences GmbH
`
`Daralyn J. Durie
`Adam R. Brausa
`Eric C. Wiener
`Annie A. Lee
`Shaelyn K. Dawson
`MORRISON & FOERSTER LLP
`425 Market Street
`San Francisco, CA 94105-2482
`(415) 268-6080
`
`Kira A. Davis
`MORRISON & FOERSTER LLP
`707 Wilshire Boulevard
`Los Angeles, CA 90017-3543
`(213) 892-5200
`
`David N. Tan
`MORRISON & FOERSTER LLP
`2100 L Street, NW, Suite 900
`Washington, DC 20037
`(202) 887-1500
`Attorneys for Plaintiff Arbutus
`Biopharma Corporation
`
`Dated: February 28, 2024
`
`
`
`3
`
`

`

`Case 1:22-cv-00252-MSG Document 361-3 Filed 06/21/24 Page 5 of 6 PageID #: 21789
`
`CERTIFICATE OF SERVICE
`
`I hereby certify that on February 28, 2024, this document was served on the persons
`
`listed below in the manner indicated:
`
`BY EMAIL:
`Jack B. Blumenfeld
`Brian P. Egan
`Travis J. Murray
`MORRIS, NICHOLS, ARSHT & TUNNELL LLP
`1201 North Market Street
`P.O. Box 1347
`Wilmington, DE 19899
`(302) 658-9200
`jblumenfeld@morrisnichols.com
`began@morrisnichols.com
`tmurray@morrisnichols.com
`
`Patricia A. Carson, Ph.D.
`Jeanna M. Wacker
`Mark C. McLennan
`Nancy Kaye Horstman
`Shaoyao Yu
`Caitlin Dean
`KIRKLAND & ELLIS LLP
`601 Lexington Avenue
`New York, NY 10022
`(212) 446-4800
`patricia.carson@kirkland.com
`jeanna.wacker@kirkland.com
`mark.mclennan@kirkland.com
`kaye.horstman@kirkland.com
`shaoyao.yu@kirkland.com
`caitlin.dean@kirkland.com
`
`Alina Afinogenova
`KIRKLAND & ELLIS LLP
`200 Clarendon Street
`Boston, MA 02116
`(617) 385-7500
`alina.afinogenova@kirkland.com
`
`James F. Hurst
`KIRKLAND & ELLIS LLP
`300 North LaSalle
`Chicago, IL 60654
`(312) 862-2000
`james.hurst@kirkland.com
`
`Yan-Xin Li
`Laura Ashley Harris
`KIRKLAND & ELLIS LLP
`555 California Street, 27th Floor
`San Francisco, CA 94104
`(415) 439-1400
`yanxin.li@kirkland.com
`auraashley.harris@kirkland.com
`
`
`
`
`
`
`
`
`
`
`
`
`4
`
`

`

`Case 1:22-cv-00252-MSG Document 361-3 Filed 06/21/24 Page 6 of 6 PageID #: 21790
`
`
`
`
`
`
`
`/s/ Nathan R. Hoeschen
`John W. Shaw (No. 3362)
`Karen E. Keller (No. 4489)
`Nathan R. Hoeschen (No. 6232)
`SHAW KELLER LLP
`I.M. Pei Building
`1105 North Market Street, 12th Floor
`Wilmington, DE 19801
`(302) 298-0700
`jshaw@shawkeller.com
`kkeller@shawkeller.com
`nhoeschen@shawkeller.com
`Attorneys for Plaintiffs
`
`5
`
`